|
| Effect analysis of Shenlian Capsule combined with osimertinib on advanced EGFR mutated non-small cell lung cancer （qi and yin deficiency syndrome） |
| Hits 317 Download times 182 Received:October 10, 2023 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2024.04.06 |
| Key Words
Shenlian Capsule;osimertinib;advanced non-small cell lung cancer with EGFR mutation;qi and yin deficiency syndrome;curative effect |
| Author Name | Affiliation | | LI Jing | The First Ward of Department of Respiratory and Critical Care Medicine, Handan Central Hospital, Handan 056001, China | | WANG Xiaoying | The First Ward of Department of Respiratory and Critical Care Medicine, Handan Central Hospital, Handan 056001, China | | WU Miao | The First Ward of Department of Respiratory and Critical Care Medicine, Handan Central Hospital, Handan 056001, China | | LI Xiaojin | Department of Oncology, Shexian Traditional Chinese Medicine Hospital, Handan 056400, China |
|
| Abstract
|
| [Objective] To investigate the curative effect of Shenlian Capsule combined with osimertinib on advanced EGFR mutated non-small cell lung cancer（qi and yin deficiency syndrome）. [Methods] A total of 110 patients with advanced non-small cell lung cancer with EGFR mutation admitted to our hospital from April 2021 to April 2022 were randomly divided into two groups. The control group（55 cases） was given osimertinib，and the study group（55 cases） was given Shenlian Capsule on the basis of the control group. The therapeutic effect，drug safety，European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 43（EORTCQLQ-LC43） scores，carcinoembryonic antigen（CEA），cytokeratin 19 fragment（CYFRA21-1），carbohydrate antigen 125（CA125） were compared between the two groups. [Results] The total effective rate of the study group was higher than that of the control group（P<0.01）. After treatment，the levels of serum CEA，CA125 and CYFRA21-1 in the two groups were obviously lower than those before treatment（P<0.01），and the levels of serum CEA，CA125 and CYFRA21-1 in the study group were obviously lower than those in the control group（P<0.05）. The incidence of adverse reactions in the study group was lower than that in the control group（P<0.05）. After treatment，the role function，physiological function，cognitive function，social function，emotional function，and overall health status scores of patients in the study group and control group were significantly increased compared to before treatment（P<0.05）. After treatment，the role function，physiological function，cognitive function，social function，emotional function，and overall health status scores of the study group were higher than those of the control group（P<0.05）. [Conclusion] Shenlian Capsule combined with osimertinib is effective and safe in the treatment of advanced EGFR non-small cell lung cancer（qi and yin deficiency syndrome）. It can also effectively reduce the levels of serum CEA，CA125 and CYFRA21-1，improve the quality of life of patients. and has broad clinical application prospects. |
|
